GeneDx Holdings Corp. (WGS)

Market Cap	2.68B
Revenue (ttm)	305.45M
Net Income (ttm)	-52.29M
Shares Out	28.07M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	103.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	622,386
Open	96.15
Previous Close	98.28
Day's Range	93.00 - 96.15
52-Week Range	8.63 - 115.60
Beta	2.00
Analysts	Strong Buy
Price Target	82.60 (-13.51%)
Earnings Date	Apr 30, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company is headquartered in Stamford, Connecticut.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Employees: 1,000
• Stock Exchange: NASDAQ
• Ticker Symbol: WGS
• Website: https://www.genedx.com

Financial Performance

In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $82.6, which is a decrease of -13.51% from the latest price.

Price Target

$82.6

(-13.51% downside)

Analyst Consensus: Strong Buy